MIT neuroscientists have made a breakthrough in treating fragile X syndrome by leveraging a novel neurotransmitter signaling ...

This study provides evidence that single-cell multi-omics profiling can reveal key regulators of HIV-1 persistence and early immune dysregulation, particularly implicating KLF2 and Th17 cells as major ...

This valuable work presents how PRDM16 plays a critical role during colloid plexus development, through regulating BMP signaling. Solid evidence supports the context-dependent gene regulatory ...

Scientists discovered years ago that the hypothalamus—which helps to manage body temperature, hunger, sex drive, sleep and ...

Scientists discovered years ago that the hypothalamus - which helps to manage body temperature, hunger, sex drive, sleep and more - includes neurons that express the protein opsin 3 (OPN3).

Researchers at Brown University and Cincinnati Children’s found that suppressing opsin 3 in the brain of mice makes them eat ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) will likely be announcing its earnings results before the market ...

Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a registered direct offering and a concurrent private ...